Hartford Financial Management Inc. - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.

Quarter-by-quarter ownership
Hartford Financial Management Inc. ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$496
-18.8%
180.0%0.00%
Q2 2023$611
-5.7%
180.0%0.00%
Q1 2023$648
-19.2%
180.0%0.00%
Q4 2022$802
-19.8%
180.0%0.00%
Q3 2022$1,0000.0%180.0%0.00%
Q1 2022$1,0000.0%180.0%0.00%
Q4 2021$1,0000.0%180.0%0.00%
Q3 2021$1,0000.0%180.0%0.00%
Q2 2021$1,000180.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2023
NameSharesValueWeighting ↓
Kynam Capital Management, LP 1,605,390$71,552,23210.98%
Octagon Capital Advisors LP 761,398$33,935,5095.28%
TSP Capital Management Group, LLC 269,895$12,029,2254.50%
Redmile Group, LLC 1,977,451$88,134,9913.60%
COMMODORE CAPITAL LP 495,823$22,0993.33%
Tri Locum Partners LP 176,109$7,849,0003.18%
ACUTA CAPITAL PARTNERS, LLC 115,000$5,125,5503.15%
Ikarian Capital, LLC 267,476$11,921,4062.88%
RTW INVESTMENTS, LP 3,084,215$137,463,4632.81%
Eversept Partners, LP 558,774$24,904,5572.18%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders